within Pharmacolibrary.Drugs.C_CardiovascularSystem.C02D_ArteriolarSmoothMuscleAgentsActingOn.C02DB01_Dihydralazine;

model Dihydralazine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 2.9166666666666663e-05,
    adminDuration = 600,
    adminMass = 25 / 1000000,
    adminCount = 1,
    Vd = 0.0025,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dihydralazine</td></tr><tr><td>ATC code:</td><td>C02DB01</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>25</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>25</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dihydralazine is a direct-acting vasodilator of the hydrazinophthalazine class, related to hydralazine. It was previously used in the management of moderate to severe hypertension, especially in parenteral administration for hypertensive emergencies, but it is not commonly approved or widely used today in many countries.</p><h4>Pharmacokinetics</h4><p>Estimated one-compartment model pharmacokinetic parameters for an adult population based on limited published information; specific studies are lacking.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C02DB01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dihydralazine;
